Tetra Bio-Pharma Inc. (TSXV:TBP), a cannabis biopharma stock, climbed after announcing that it has signed a research and development agreement with Constance Therapeutics
A drug development deal pushed a cannabis biopharma stock sharply higher Thursday. Here’s some small stocks making big moves on Thursday, December 14, 2017 (as of 4 pm EST):
Tetra Bio-Pharma Inc. (TSXV:TBP), a cannabis biopharma stock, powered 24% higher to $1.02 on Thursday after announcing that it has signed an exclusive research and development agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their medicinal cannabis extract products.
As well, shares of Internet of Things Inc. (TSXV:ITT) slipped 4% to $0.12 as the software and solutions provider to the Internet of Things market said it has formed a new subsidiary, Blockchain of Things Inc.
LGC Capital Ltd. (TSXV:LG), meanwhile, reported that it has now received confirmation from the Australian Government’s Office of Drug Control to increase its interest in Medical Cannabis company Habi Pharma Pty Ltd, doing business as Little Green Pharma, above 4.99% and is now increasing its strategic interest to 11.91%. Little Green Pharma just began planting its first medical cannabis crop in Australia. LGC Capital stock popped 11% to $0.45 following the announcement.
Finally, Wavefront Technology Solutions Inc. (TSXV:WEE) shares jumped 27% to $0.285 after the provider of fluid injection technology for oil and gas well stimulation and oil recovery announced that a new, seven well Powerwave Odyssey custom stimulation campaign has been initiated in the Kingdom of Saudi Arabia.
Disclosure: Neither the author nor any of the principals at SmallCapPower, or their family members, own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Tetra Bio-Pharma Inc. (TSXV:TBP), a cannabis biopharma stock, powered 24% higher to $1.02 on Thursday after announcing that it has signed an exclusive research and development agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their medicinal cannabis extract products.
